ES2305245T5 - Locus de la cadena ligera lambda de ratón - Google Patents
Locus de la cadena ligera lambda de ratón Download PDFInfo
- Publication number
- ES2305245T5 ES2305245T5 ES02732970.5T ES02732970T ES2305245T5 ES 2305245 T5 ES2305245 T5 ES 2305245T5 ES 02732970 T ES02732970 T ES 02732970T ES 2305245 T5 ES2305245 T5 ES 2305245T5
- Authority
- ES
- Spain
- Prior art keywords
- cells
- light chain
- mice
- chain
- lambda light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Position Input By Displaying (AREA)
- Inspection Of Paper Currency And Valuable Securities (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Mechanical Coupling Of Light Guides (AREA)
- Details Of Television Scanning (AREA)
- User Interface Of Digital Computer (AREA)
Description
5
10
15
20
25
30
35
40
45
50
55
60
65
normales mantenidos en las mismas condiciones libres de patógenos (Tabla 1). Los anticuerpos de suero en λ1-/-κ-/y λ1.3-/-κ-/-fueron también reducidos pero comparables con aquellos en ratones κ-/-(Zou, X. y otros, 1995, supra). Inesperadamente ratones λ1.3.2-/-κ-/-y λ1-2∆-/-κ-/-derivados de hembras heterocigóticas o madres adoptadas tuvieron títulos de anticuerpos significativos en el suero aún detectables por ELISA 6 semanas después del destete. Sin embargo, los análisis de suero de tales ratones después de 3 meses no mostraron anticuerpos remanentes (datos no mostrados). La pérdida de Ig de suero en ratones λ1.3.2-/-κ-/-confirmó que Cλ4 tiene que ser seudogen que los genes Vλ remanentes no pueden ser expresados usando un gen C todavía desconocido. La reducción del nivel de células B en la médula ósea y el bazo a cada etapa de silenciamiento sucesiva es mostrado en la Fig. 2 y la Tabla 1. En la médula ósea el desarrollo de las células pro y pre-B parece estar un poco afectado por la pérdida de la expresión de la cadena L y los niveles de c-kit+, las células B CD43+, y CD25+ son bastante similares en las cepas KO y comparadas con los ratones normales (Fig. 2a). Sin embargo, en la etapa cuando el reordenamiento de la cadena L debería haber sido completado el desarrollo normal es bloqueado y las células B inmaduras fallan para expresar la IgM de superficie. De manera interesante, es claramente visible una reducción en el número de células que expresan la IgM de superficie y, comparado al 12 % de IgM de linfocitos B220+ en la médula ósea de ratones normales, 4 % son encontrados en ratones κ-/-, 2 % en ratones λ1-/-κ-/-, 1 % en λ1.3-/-κ-/-y esencialmente ninguno en ratones λ1.3.2-/-κ-/-y λ1-2∆-/-κ-/-. En el bazo los niveles de células B Ig+ en ratones λ1-/-κ-/-y λ1.3-/-κ-/-son similares a aquellos en ratones κ-/-mientras que en ratones λ1.3.2-/-κ-/-y λ1-2∆-/-κ-/-solo una tinción de fondo es remanente (Fig. 2b). Para evaluar si las células B B220+ en la médula ósea acumulan cadena H µ en el citoplasma y si esas células migran a órganos linfoides secundarios se tiñó para el IsM citoplasmático. Como se muestra en la figura 3a las células B de la médula ósea CD25+ provenientes de ratones λ1-2∆-/-κ-/-ciertamente se tiñen para la cadena H µ citoplasmática pero no muestran teñimiento para la IgM de superficie. Ciertamente los niveles de células B CD25+ y su distribución de tamaños es muy similar en ratones normales y L KO (Fig. 3b). Sin embargo, la migración de estas células a, por ejemplo, el peritoneo no tiene lugar y la Fig 4 muestra que esencialmente ninguna célula B existe en los órganos linfoides secundarios. Hubo sorpresa porque la cadena H µ identificada en el citoplasma de las células B de los ratones λ1-2∆-/-κ-/-es del mismo tamaño o peso molecular que la cadena H µ convencional. La lisis celular usando digitonina y capturando las cadenas H µ enlazadas y no enlazadas, analizadas en geles de poliacrilamida (Fig.5), no mostró diferencias de tamaño de la cadena H µ producida en el citoplasma de ratones silenciada de cadena L o normal. Sin embrago, como se mostró también en la Fig. 5 la Ig de suero no es producida por esos ratones. Esto re-enfatiza que el desarrollo de las células B y la expresión de la cadena H µ hasta la etapa cuando las cadenas L son expresadas parece no ser ampliamente afectada en ratones KO de cadena L. Además, la pérdida de la cadena L evita la liberación de la cadena H µ desde la célula lo cual evita la secreción de Ig.
Bloqueo en el desarrollo en la etapa de células B inmaduras. El silenciamiento de los genes de la cadena L λ en el fondo de κ-/-mostró que no es producida Ig secretada ni de superficie y que el bloqueo resultante en el desarrollo de las células B está establecido en la fase de transición de preB II a inmadura. En esta etapa la expresión de CD25 es revocada, el pre BCR es reemplazado por el BCR, la cadena L no es expresada y el reordenamiento de la cadena L κ o λ es completado con la expresión exitosa que permite la asociación de la cadena H µ. Después de algunas divisiones las células pre B-II de CD25+ grandes se diferencian en células pre B-II que mantienen CD25+ pequeños las cuales están en el proceso de reordenamiento de sus genes de cadena L. Como puede ser observado en la Fig. 2a el número de células CD25+B220+ en la etapa inmediatamente antes del bloqueo desarrollado es muy similar. Como el reordenamiento exitoso de la cadena L es evitado o impedido en los ratones mutantes hubo sorpresa porque este bloqueo altera la relación de células CD25+ pequeñas y grandes. En la Fig.3b el número de células de la médula ósea CD25* de ratones κ-/-y λ1-2∆-/-κ-/-, normales de edad similar es trazado contra el tamaño celular. La comparación muestra ligeras variaciones como se esperaba pero no diferencias importantes en las poblaciones de células pre B-II grandes y pequeñas. Esto concluye que la falla para expresar cadenas L inicia un completo bloqueo en el desarrollo de la etapa de células B inmaduras cuando la IgM de superficie debería ser expresada. Además no se acumulan células B inmaduras antes del evento.
Este bloqueo en el desarrollo con recobrados no evidentes impide la expresión IgM de superficie y la subsecuente migración celular. Como se muestra en la Tabla 1 el número de células del bazo en ratones λ1.3.2-/-κ-/-y λ1-2∆-/-κ-/-es significativamente reducida. Una pérdida completa de las células B maduras es también encontrada en la cavidad del peritoneo con células no B 220+ y B 220+CD5+. (Fig.4). Esta pérdida de células B-1 y B-2 parece no tener efecto en los niveles de células T las cuales son mantenidos.
Discusión
Los experimentos mostraron que el desarrollo de las células B es abortado en los ratones con la deleción de la cadena L en la etapa de transición de células B pre BII a inmaduras cuando la expresión del receptor de superficie debería haber sido lograda. Este completo bloqueo en el desarrollo evita la maduración de las células B y el ratón es inmunodeficiente con respecto a las células B que expresan anticuerpos. La cadena L correspondiente codificada por VpreB y λ5 no sostiene el desarrollo de células B y con la falla para expresar polipéptidos de la cadena L la diferenciación de células B cesa exactamente en la etapa cuando el reordenamiento de la cadena L debería haber sido completado. Esto reenfatiza la importancia de la cadena L para el desarrollo inmune y que, al menos en el ratón, no hay gen o eventos de rescate que puedan compensar la deficiencia de la cadena L.
7
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0115256 | 2001-06-21 | ||
| GBGB0115256.0A GB0115256D0 (en) | 2001-06-21 | 2001-06-21 | Mouse light chain locus |
| PCT/GB2002/002867 WO2003000737A2 (en) | 2001-06-21 | 2002-06-21 | MOUSE μ LIGHT CHAIN LOCUS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2305245T3 ES2305245T3 (es) | 2008-11-01 |
| ES2305245T5 true ES2305245T5 (es) | 2015-12-11 |
Family
ID=9917128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02732970.5T Expired - Lifetime ES2305245T5 (es) | 2001-06-21 | 2002-06-21 | Locus de la cadena ligera lambda de ratón |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7541513B2 (es) |
| EP (2) | EP1956092A1 (es) |
| AT (1) | ATE393826T1 (es) |
| AU (1) | AU2002304460A1 (es) |
| CY (1) | CY1108227T1 (es) |
| DE (1) | DE60226322T3 (es) |
| DK (1) | DK1399559T4 (es) |
| ES (1) | ES2305245T5 (es) |
| GB (2) | GB0115256D0 (es) |
| PT (1) | PT1399559E (es) |
| WO (1) | WO2003000737A2 (es) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| GB0115256D0 (en) * | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| GB0228210D0 (en) * | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| US7141157B2 (en) * | 2003-03-11 | 2006-11-28 | Chevron U.S.A. Inc. | Blending of low viscosity Fischer-Tropsch base oils and Fischer-Tropsch derived bottoms or bright stock |
| US8783257B2 (en) | 2004-02-23 | 2014-07-22 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| EP3738636B1 (en) | 2006-07-14 | 2023-06-07 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
| PL2602323T3 (pl) | 2007-06-01 | 2018-06-29 | Open Monoclonal Technology, Inc. | Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego |
| US10792451B2 (en) | 2008-05-12 | 2020-10-06 | Fisher & Paykel Healthcare Limited | Patient interface and aspects thereof |
| US20100122358A1 (en) * | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
| JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| ES2724975T3 (es) * | 2009-12-10 | 2019-09-18 | Regeneron Pharma | Ratones que producen anticuerpos de cadena pesada |
| ES2984483T3 (es) | 2010-03-31 | 2024-10-29 | Ablexis Llc | Ingeniería genética de ratones para la producción de anticuerpos quiméricos |
| PT3034608T (pt) | 2010-06-22 | 2019-05-28 | Regeneron Pharma | Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| CN103025884B (zh) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| EP4640259A3 (en) | 2010-10-08 | 2025-11-12 | Fisher & Paykel Healthcare Limited | Mask seal assembly |
| EP2638155A1 (en) | 2010-11-08 | 2013-09-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| US10603456B2 (en) | 2011-04-15 | 2020-03-31 | Fisher & Paykel Healthcare Limited | Interface comprising a nasal sealing portion |
| CA2833106C (en) | 2011-04-15 | 2019-08-27 | Fisher & Paykel Healthcare Limited | Interface comprising a rolling nasal bridge portion |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| EP2758534B1 (en) | 2011-09-19 | 2020-04-29 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| SG10201605675WA (en) | 2011-12-20 | 2016-09-29 | Regeneron Pharma | Humanized light chain mice |
| SG11201405059XA (en) | 2012-03-28 | 2014-09-26 | Kymab Ltd | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| EP3841876A1 (en) | 2013-03-14 | 2021-06-30 | Erasmus University Medical Center Rotterdam | Transgenic mouse for antibody production |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| DK3209698T4 (da) | 2014-10-22 | 2022-04-04 | Crescendo Biologics Ltd | Transgene mus |
| GB201500464D0 (en) | 2015-01-12 | 2015-02-25 | Crescendo Biolog Ltd | Method of producing optimised therapeutic molecules |
| GB201500463D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| EP3402825A1 (en) | 2016-01-12 | 2018-11-21 | Crescendo Biologics Limited | Molecules that bind prostate specific membrane antigen (psma) |
| EP4414484A3 (en) | 2016-02-04 | 2025-01-15 | Trianni, Inc. | Enhanced production of immunoglobulins |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| GB201612043D0 (en) | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| MX2019005552A (es) | 2016-11-14 | 2019-08-12 | Amgen Inc | Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas. |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| EP3565841A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| IL268049B2 (en) | 2017-01-19 | 2025-08-01 | Omniab Inc | Transgenic rodent human antibodies with multiple immunoglobulin heavy chain loci |
| USD824020S1 (en) | 2017-02-23 | 2018-07-24 | Fisher & Paykel Healthcare Limited | Cushion assembly for breathing mask assembly |
| USD823455S1 (en) | 2017-02-23 | 2018-07-17 | Fisher & Paykel Healthcare Limited | Cushion assembly for breathing mask assembly |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| EP3710478A1 (en) | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| BR112020024074A2 (pt) | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| GB2576914A (en) | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
| KR20210086651A (ko) | 2018-10-26 | 2021-07-08 | 테네오바이오, 인코포레이티드 | Cd38에 결합하는 중쇄 항체 |
| GB201818460D0 (en) | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| CA3125380A1 (en) | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| WO2020229844A1 (en) | 2019-05-15 | 2020-11-19 | Crescendo Biologics Limited | Binding molecules |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| GB201914468D0 (en) | 2019-10-07 | 2019-11-20 | Crescendo Biologics Ltd | Binding Molecules |
| CN115023441A (zh) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | 与cd38结合的重链抗体 |
| IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| CN116249714A (zh) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| JP2023529846A (ja) | 2020-06-02 | 2023-07-12 | バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド | 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物 |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| KR20230148828A (ko) | 2021-02-25 | 2023-10-25 | 테네오바이오, 인코포레이티드 | 항-psma 항체 및 car-t 구조 |
| US20240182597A1 (en) | 2021-02-26 | 2024-06-06 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
| KR20230166090A (ko) | 2021-04-06 | 2023-12-06 | 테네오바이오, 인코포레이티드 | 항-cd19 항체 및 car-t 구조체 |
| CN117337303A (zh) | 2021-04-16 | 2024-01-02 | 特尼奥生物股份有限公司 | 抗cd20抗体及car-t结构 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| WO2023199069A1 (en) | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Chimeric antigen receptor that binds mesothelin |
| GB202205589D0 (en) | 2022-04-14 | 2022-06-01 | Crescendo Biologics Ltd | Mesothelin binders |
| EP4598958A1 (en) | 2022-10-05 | 2025-08-13 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| EP4512243A1 (en) | 2023-08-21 | 2025-02-26 | Kymab Limited | Binding molecules |
| CN117587070B (zh) * | 2024-01-19 | 2024-04-30 | 北京仁源欣生生物科技有限公司 | 一种经遗传修饰的非人哺乳动物的制备方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| GB9823930D0 (en) * | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| GB0115256D0 (en) * | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
-
2001
- 2001-06-21 GB GBGB0115256.0A patent/GB0115256D0/en not_active Ceased
-
2002
- 2002-06-21 WO PCT/GB2002/002867 patent/WO2003000737A2/en not_active Ceased
- 2002-06-21 GB GB0400676A patent/GB2392672B/en not_active Expired - Lifetime
- 2002-06-21 US US10/481,395 patent/US7541513B2/en not_active Expired - Fee Related
- 2002-06-21 PT PT02732970T patent/PT1399559E/pt unknown
- 2002-06-21 AT AT02732970T patent/ATE393826T1/de active
- 2002-06-21 DE DE60226322.0T patent/DE60226322T3/de not_active Expired - Lifetime
- 2002-06-21 EP EP20080008171 patent/EP1956092A1/en not_active Withdrawn
- 2002-06-21 DK DK02732970.5T patent/DK1399559T4/en active
- 2002-06-21 ES ES02732970.5T patent/ES2305245T5/es not_active Expired - Lifetime
- 2002-06-21 EP EP02732970.5A patent/EP1399559B2/en not_active Expired - Lifetime
- 2002-06-21 AU AU2002304460A patent/AU2002304460A1/en not_active Abandoned
-
2008
- 2008-07-30 CY CY20081100796T patent/CY1108227T1/el unknown
-
2009
- 2009-06-01 US US12/476,087 patent/US8367888B2/en not_active Expired - Fee Related
-
2012
- 2012-10-17 US US13/654,007 patent/US9439405B2/en not_active Expired - Fee Related
-
2016
- 2016-08-08 US US15/230,564 patent/US10194645B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB0400676D0 (en) | 2004-02-18 |
| US9439405B2 (en) | 2016-09-13 |
| GB0115256D0 (en) | 2001-08-15 |
| US20050060763A1 (en) | 2005-03-17 |
| AU2002304460A1 (en) | 2003-01-08 |
| US10194645B2 (en) | 2019-02-05 |
| US7541513B2 (en) | 2009-06-02 |
| DK1399559T3 (da) | 2008-08-25 |
| DE60226322T2 (de) | 2009-07-09 |
| DE60226322T3 (de) | 2016-03-03 |
| US20170049083A1 (en) | 2017-02-23 |
| EP1399559A2 (en) | 2004-03-24 |
| ATE393826T1 (de) | 2008-05-15 |
| EP1399559B1 (en) | 2008-04-30 |
| DE60226322D1 (de) | 2008-06-12 |
| CY1108227T1 (el) | 2014-02-12 |
| DK1399559T4 (en) | 2015-12-14 |
| GB2392672A (en) | 2004-03-10 |
| ES2305245T3 (es) | 2008-11-01 |
| WO2003000737A3 (en) | 2003-09-25 |
| US20110093961A1 (en) | 2011-04-21 |
| PT1399559E (pt) | 2008-07-29 |
| EP1399559B2 (en) | 2015-09-02 |
| US20130046079A1 (en) | 2013-02-21 |
| US8367888B2 (en) | 2013-02-05 |
| EP1956092A1 (en) | 2008-08-13 |
| GB2392672B (en) | 2005-05-11 |
| WO2003000737A2 (en) | 2003-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2305245T5 (es) | Locus de la cadena ligera lambda de ratón | |
| AU2021202371B2 (en) | Recombinant cell surface capture proteins | |
| Albers et al. | The expression of mutant epidermal keratin cDNAs transfected in simple epithelial and squamous cell carcinoma lines. | |
| Solvason et al. | An embryonic source of Ly1 but not conventional B cells | |
| Greenhalgh et al. | Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v‐Ha‐ras oncogene | |
| Kenney et al. | The PSAP motif within the ORF3 protein of an avian strain of the hepatitis E virus is not critical for viral infectivity in vivo but plays a role in virus release | |
| Bonneville et al. | Blockage of αβ T-cell development by TCR γδ transgenes | |
| Reap et al. | Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice. | |
| Gregory et al. | Epstein‐Barr virus‐transformed human precursor B cell lines: altered growth phenotype of lines with germline or rearranged but nonexpressed heavy chain genes | |
| DK1354034T3 (da) | Transgene transchromosomale gnavere til fremstilling af humane antistoffer | |
| TR200100350T2 (tr) | Newcastle hastalığı virüsü, enfeksiyon klonları, aşılar ve diyagnostik testler. | |
| Gaudin et al. | Mutations in the glycoprotein of viral haemorrhagic septicaemia virus that affect virulence for fish and the pH threshold for membrane fusion | |
| DK0787191T3 (da) | Nukleotidsekvenser som koder for antigener fra HIV-1-retrovirus gruppe (eller undergruppe) O, transmembrane kappepeptider og retoviruscapsidproteiner og -peptider | |
| Yonemochi et al. | Pericoronal hamartomatous lesions in the opercula of teeth delayed in eruption: an immunohistochemical study of the extracellular matrix | |
| DK162421C (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
| Mårtensson et al. | A transgenic marker for mouse B lymphoid precursors | |
| PT95580B (pt) | Processo para a preparacao de material biologico modificado | |
| Tevethia et al. | A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice | |
| JP4695840B2 (ja) | 不死化された抗体分泌細胞の製造方法 | |
| Suffner et al. | Domains of the hepatitis B virus small surface protein S mediating oligomerization | |
| Aguzzi et al. | Human foamy virus proteins accumulate in neurons and induce multinucleated giant cells in the brain of transgenic mice | |
| Gisselbrecht et al. | Genetic control of sensitivity to moloney‐virus‐induced leukemias in mice. I. Demonstration of multigenic control | |
| Choi et al. | A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs | |
| Wong et al. | Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer | |
| Escors et al. | The membrane M protein of the transmissible gastroenteritis coronavirus binds to the internal core through the carboxy-terminus |